Premium
COPANLISIB TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA
Author(s) -
Panayiotidis P.,
Kellner A.,
Follows G.A.,
Mollica L.,
Nagler A.,
Özcan M.,
Santoro A.,
Hiemeyer F.,
Liu L.,
GarciaVargas J.,
Childs B.H.,
Zinzani P.L.,
Dreyling M.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.69_2631
Subject(s) - medicine , clinical endpoint , gastroenterology , phases of clinical research , refractory (planetary science) , progression free survival , neutropenia , bendamustine , nausea , rituximab , tolerability , surgery , lymphoma , clinical trial , adverse effect , chemotherapy , physics , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom